Eye - diabetic macular oedema

The PBS subsidises aflibercept, dexamethasone intravitreal implant and ranibizumab for patients with diabetic macular oedema (DMO).

Patient eligibility

Treatment with aflibercept, dexamethasone intravitreal implant and ranibizumab can be subsidised through the Pharmaceutical Benefits Scheme (PBS) under the National Health Act 1953, Section 85 for patients with DMO.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits outlines the restrictions for prescribing aflibercept, dexamethasone intravitreal implant and ranibizumab.

Applications

Patients must be treated by an ophthalmologist or in consultation with an ophthalmologist to be eligible for PBS subsidised treatment with these medications.

Initial treatment

Make all initial applications for authority approval to prescribe PBS subsidised aflibercept, dexamethasone intravitreal implant and ranibizumab for the treatment of DMO in writing and:

All applications must include the completed :

If urgent, you can fax the first authority application to us on 1300 093 177 Monday to Friday during operating hours from 8 am to 5 pm AEST. Then the PBS Complex Drugs Programs Team will call you.

Continuing treatment

To make continuing applications for treatment with aflibercept, dexamethasone intravitreal implant and ranibizumab call the PBS Complex Drugs Programs enquiry line.

Further information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 1 April 2018